ABSTRACT Recruitment of inflammatory leucocytes to the airways may play a part in the pathogenesis ofasthma. As dietary enrichment with fish oil lipids can suppress leucocyte function, the effect of these lipids on asthma control and neutrophil function was studied in 20 subjects with mild asthma. Twelve subjects received capsules containing 3-2 g of eicosapentaenoic acid and 2-2 g of docosahexaenoic acid daily and eight subjects received placebo capsules containing olive oil for 10 weeks in a double blind fashion. Baseline specific airways conductance, airways responsiveness to histamine and exercise, diurnal peak expiratory flow, symptom scores, and bronchodilator use were measured. Neutrophil fatty acid composition was evaluated by gas chromatography, calcium ionophore induced neutrophil leukotriene (LT)B4 and LTB5 generation were measured by reverse phase high performance liquid chromatography and radioimmunoassay, and neutrophil chemotactic responses to formyl-methionyl-leucyl-phenylalanine (FMLP) and LTB4 were assessed by a microchemotaxis technique. Although the fish oil supplemented diet produced a greater than 10 fold increase in the eicosapentaenoic acid content of neutrophil phospholipids, there was no significant change in airways responsiveness to histamine or any change in any of the clinical measurements. After dietary supplementation with fish oil there was a 50% inhibition of total LTB (LTB4 + LTB5) generation by ionophore stimulated neutrophils and neutrophil chemotaxis was substantially suppressed. Neutrophil function remained unchanged in the placebo group. It is concluded that in subjects with mild asthma a fish oil enriched diet attenuates neutrophil function without changing the severity of asthma.
responses to formyl-methionyl-leucyl-phenylalanine (FMLP) and LTB4 were assessed by a microchemotaxis technique. Although the fish oil supplemented diet produced a greater than 10 fold increase in the eicosapentaenoic acid content of neutrophil phospholipids, there was no significant change in airways responsiveness to histamine or any change in any of the clinical measurements. After dietary supplementation with fish oil there was a 50% inhibition of total LTB (LTB4 + LTB5) generation by ionophore stimulated neutrophils and neutrophil chemotaxis was substantially suppressed. Neutrophil function remained unchanged in the placebo group. It is concluded that in subjects with mild asthma a fish oil enriched diet attenuates neutrophil function without changing the severity of asthma.
Asthma is characterised by airways inflammation, by bronchial hyperresponsiveness to non-specific stimuli, and by episodic and reversible airflow obstruction. Studies both in experimental animals and in man have indicated an association between airways hyperresponsiveness and bronchial inflammation.'-' It has been suggested that airway inflammation may be central to the pathophysiology of bronchial asthma.
Eicosapentaenoic acid and docosahexaenoic acid are polyunsaturated fatty acids derived from fish oil.
They are termed omega-3 (C43) or N-3 fatty acids because the first double bond in the molecule is three carbons removed from the terminal methyl group. These fatty acids competitively inhibit the formation 22 of whom were atopic, entered this double blind and placebo controlled study. Eleven subjects were taking regular inhaled corticosteroids, one subject was taking a long acting oral theophylline preparation at night, and all subjects used inhaled f2 adrenergic agonists as required. No one was taking an oral corticosteroid, and no one gave a history of aspirin sensitivity. All subjects gave informed consent and the study was approved by the Guy's Hospital ethical committee.
The study began with an initial run in period of two to four weeks, during which diary card records were kept, and a baseline exercise or histamine challenge test (or both) was performed. During this period peripheral blood neutrophils were purified for analysis of fatty acid composition and evaluation of function: calcium ionophore induced generation of leukotriene B compounds (LTB4 and LTB5), and assessment of chemotactic responsiveness to formyl-methionylleucyl-phenylalanine (FMLP) and LTB4. Subjects were then randomised to receive 18 capsules a day of Max-EPA (3-2 g eicosapentaenoic acid and 2-2 g docosahexaenoic acid) or identical placebo capsules containing olive oil for 10 weeks. Their usual diets were unchanged. Diary cards were filled in throughout the study period. At the end of the 10 week study, exercise and histamine challenge tests were repeated and neutrophil fatty acid composition and function were assessed again. Inhaled f02 agonists and inhaled steroids were withheld for 12 hours and oral theophylline for 48 hours before each exercise and histamine challenge test. Subjects who had a skinprick test reaction to mixed grass,pollen of 3 mm or greater than the saline control were not studied during MaySeptember, and subjects with a positive skinprick test reaction to Dermatophagoides pteronyssinus were not studied during September-December. DIARY 
CARDS
Symptoms of nocturnal cough, nocturnal wheeze, and daytime wheeze were assesssed separately by the subjects every day on a scale of 0 (symptom free) to 3 (severe). Daily medication was also recorded. Subjects were instructed in the correct use of a Wright's mini peak flow meter and they recorded the best of three peak flow measurements morning and evening. Symptom scores, morning and evening expiratory peak flow rates, and bronchodilator use in the last two weeks of the control period were compared with those observed in the last two weeks of the treatment period. Symptom scores and the number of doses of bronchodilator used during each two week assessment period were summed separately. Morning and evening peak flow rates were averaged for each two week assessment period. In addition, the difference between morning and evening peak flow rates on each day was expressed as a percentage of the higher figure and used as a measure of airways lability. The average airways lability for each of the two week assessment periods was calculated.
Arm, Horton, Mencia-Huerta, House, Eiser, Clark, Spur, Lee They wore a nose clip and undertook eight minutes of exercise on a mechanically braked bicycle ergometer at 60-130 watts (Body Gu#rd 990, Ogloend, Norway).
The work load was adjusted to produce about 80% of maximal predicted oxygen consumption. The exercise was undertaken at ambient temperature and humidity. The pulse rate was measured before and at one minute intervals during exercise. Specific airways conductance (sGaw) was measured before exercise and 5, 10, 15, 30, 45, and 60 minutes after exercise.
HISTAMINE CHALLENGE
Inhalation challenge was performed with a Hudson nebuliser linked to a breath activated dosimeter.22
Delivery of air to the nebuliser was regulated to a pressure of 149 kPa (20 lb/in2) for 0-6 second from the start of each inspiration. After baseline measurements of sGaw subjects inhaled five breaths of phosphate buffered saline. Ifthe decrease in sGaw was under 10% the patients were subjected to histamine challenge. Two fold increases in the concentration of histamine acid phosphate (Sigma, Dorset) diluted in phosphate buffered saline were inhaled from a starting concentration of 0 5 mg/ml. sGaw was measured at two minute intervals after each inhalation of histamine and increasing concentrations of histamine were administered until a greater than 35% fall in sGaw was achieved. The cumulative dose of histamine required to produce a 35% fall in sGaw (histamine PD35 sGaw) was determined by linear interpolation from the histamine log dose-response curve.
MEASUREMENTS OF SGAW
Measurements of sGaw were made in a total body plethysmograph linked to a digital computer.23 Four to six measurements of sGaw were recorded at each time point and the mean value was calculated. Baseline sGaw was over 0 9 s-' kPa-' before each challenge. (BDH) , and stored at -70C under nitrogen before analysis for fatty acid composition by gas chromatography. '9 After the removal of neutrophils for lipid extraction, the remaining cells were used whenever possible for assessment of chemotactic responses to FMLP (Sigma) and LTB4, and for measurement of the quantities of LTB4 generated by neutrophils stimulated by calcium ionophore (A23187) (Calbiochem, La Jolla, California) under optimal conditions. Chemotaxis was assessed by a microchemotaxis method.'4 Results were expressed as the number of neutrophils per five high power fields after correction for background migration. The assay, which has an intra-assay coefficient of variation of 19-5%, was performed in duplicate. Calcium ionophore was dissolved at 10 mmol/l in dimethyl sulphoxide (BDH) and diluted to specific concentrations in Hanks' balanced salt solution (Flow Laboratories, Rickmansworth, Herts) containing calcium and magnesium, 30 mM N-2-hydroxyethyl-piperazine-N-2-ethane sulfonic acid (HEPES) (Sigma) and 0-1% bovine serum albumin (Sigma). Two x 10 neutrophils in 500 p1 of buffer were preincubated at 37°C for 10 minutes before the addition of 500 pl of buffer containing A23 187 to achieve a final concentration of 10 pmol/l, or with 500 kl of buffer alone as a control. The mixture was incubated for 10 minutes at 37°C. The reaction was stopped by rapid cooling on ice and centrifugation at 10 000 g for 30 seconds. The supernatant was removed and stored at -20°C.
Generation of LTB4 and LTB5 was assayed by reverse phase high performance liquid chromatography and radioimmunoassay.'826 Briefly, supernatants were applied to a 10 gm C18 Ultrasil ODS column (4-6 x 250 mm, Beckman Instruments, Berkeley, California). The products were eluted at 1 ml/min in 63% methanol (BDH), 36-9% water, 0-1% (vol/vol) acetic acid, pH 5-6 for 30 minutes. One millilitre fractions were collected. Duplicate 100 p1 samples of each fraction were evaporated to dryness under negative pressure, then each was resuspended in 100 p1 of isogel tris buffer and measured for immunoreactive LTB4 and LTB5 by radioimmunoassay. The column was calibrated for the retention times of synthetic leukotrienes: LTB5 (12-2 (SEM 0-4) min, n = 10); (5S12R)-6-trans LTB4 (15-1 (0 5) min, n = 10); (5S, 12S)-6-trans-LTB4 (16- 
Results
Twenty subjects completed the trial. Five individuals did not complete the study: three subjects found the number and size of capsules unmanageable; one subject withdrew from the study owing to personal circumstances; one subject started the study but was withdrawn because three weeks after starting the diet she required admission to hospital for acute asthma. The fatty acid content of neutrophil phospholipids was assessed in all subjects. Arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid comprised 12-9% (SEM 3-7%), 0-1% (0-1%), and 2-8% (0-7%) of the total neutrophil fatty acid content of subjects before dietary supplementation with placebo capsules, and 14-6% (2-7%), 0-2% (0-1%), and 2-2% (0-6%) in subjects before supplementation with Max-EPA. The neutrophil eicosapentaenoic acid content remained unchanged after placebo capsules, but rose to 2-6% (0-5%) of 
Discussion
Both eicosapentaenoic acid and docosahexaenoic acid are prominent in fish oil enriched diets. Eicosapentaenoic acid is a better substrate and docosahexaenoic acid is a substantially worse substrate for product generation by the 5-lipoxygenase pathway than is arachidonic acid.27 Docosahexaenoic acid has little effect on arachidonic acid metabolism by the 5-lipoxygenase pathway, whereas eicosapentaenoic acid leads to the elaboration of less LTB4'2 and yields a structurally analogous product LTB5, which has reduced biological activity.'"'5 Dietary supplementation with fish oil in the form of Max-EPA for six weeks Since bronchial inflammation and infiltrating leucocytes may be important in the pathogenesis of asthma,'-9 we have studied the effects of inhibition of neutrophil function through the provision of fish oil lipids on non-specific airway hyperresponsiveness and the severity of asthma.
The study was conducted in a placebo controlled and double blind manner and carried out with a parallel rather than a crossover design because we could not predict the duration of any clinical effect of dietary supplementation with eicosapentaenoic acid. The fish oil lipids were provided in the form of Max-EPA, which consists mainly of triglycerides, with 34% ofthe total fatty acids and 86% of the polyunsaturated fatty acids consisting of eicosapentaenoic acid and docosahexaenoic acid. The dose of eicosapentaenoic acid we selected for study is the dose that has previously been shown to have anti-inflammatory potential on the basis of its effect on leucocyte function. 8 The airway responses to histamine and exercise were used to assess changes in non-specific bronchial responsiveness during dietary supplementation with fish oil lipids. In addition, symptom scores, bronchodilator use, and airway lability as measured by diurnal variations in peak flow were carefully 
